DavidMNanusMD

PubMed

• The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution.
  Duy D Nguyen, William F Hooper, Weisi Liu, Timothy R Chu, Heather Geiger
  Nature. 2024-11-01
• [Corrigendum] Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.
  Katsuyuki Iida, Rong Zheng, Ruoqian Shen, David M Nanus
  International Journal of Oncology. 2024-11-01
• 2 citations
  The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
  Susan Halabi, Siyuan Guo, Joseph J Park, David M Nanus, Daniel J George
  Clinical Cancer Research. 2024-03-15

Journal Articles

• Analyses of the transcriptome and metabolome demonstrate that HIF1alpha mediates altered tumor metabolism in clear cell renal cell carcinoma  
  Minton DR, Fu L, Chen Q, Robinson BD, Gross SS, Nanus DM, Gudas LJ, Plos One, 1/1/2015
• Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTA- huJ591 anti prostate specific membrane antigen specific monoclonal antibody  
  Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, Bander NH, Goldsmith SJ, Curr Radiopharm, 1/1/2015
• Genome-wide Profiling of TRACK kidneys shows similarity to the human ccRCC transcriptome  
  Fu L, Minton DR, Zhang T, Nanus DM, Gudas LJ, Mol Cancer Res, 1/1/2015
• Integrative clinical sequencing analysis of metastatic castration resistant prostate cancer reveals a high frequency of clinical actionability  
  Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera JM, Montgomery R, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida WM, Bradley RK, Vinson J, Cao X..., Cell, 1/1/2015
• Whole exome sequencing of metastatic cancer and biomarkers of treatment response  
  Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J, Park K, Banfelder J, Prandi D, Madhukar N, Zhang T, Padilla J,..., JAMA Oncol, 1/1/2015
• A Phase I/II study for analytic validation of 89zr-J591 immunopet as a molecular imaging agent for metastatic prostate cancer  
  Pandit-Taskar N, O'Donoghue J, Durack J, Lyashchenko S, Cheal S, Beylergil V, Lefkowitz R, Carrasquillo J, Martinez D, Fung AM, Solomon S, Gonen M, Heller G, Loda M, N..., Clin Cancer Res, 1/1/2015
• Cytotoxic chemotherapy in the treatment of advanced renal cell carcinoma in the era of targeted therapy  
  Diamond E, Molina AM, Carbonaro M, Akhtar NH, Giannakakou P, Tagawa ST, Nanus DM, Crit Rev Oncol Hematol, 1/1/2015
• The initial detection and partial characterization of circulating tumor cells in neuroendocrine prostate cancer  
  Beltran H, Jendrisak A, Landers M, Mosquera JM, Kossai M, Louw J, Krupa R, Graf RP, Schreiber N, Nanus DM, Tagawa ST, Marrinucci D, Dittamore R, Scher HI, Clin Cancer Res, 1/1/2015
• Kidney cancer: novel targets in altered tumour metabolism  
  Minton DR and Nanus DM, Nature Rev Urol, 1/1/2015
• CANCER Cancer therapies that are gone with the Wnt  
  Nanus DM and Giannakakou P, Science, 1/1/2015
• The tale of two hypoxia-inducible factors in renal cell carcinoma  
  Nanus DM and Gudas LJ, Eur Urol, 1/1/2015
• Double blind randomized phase II trial of maintenance sunitinib versus placebo following response to chemotherapy for patients with advanced urothelial carcinoma  
  Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM, Dreicer D, Kohli M, Petrylak DP, Vaughn DJ, Bylow KA, Wong SG, Sottnik JL, Keller ET, Smith DC, Hussain M, Cancer, 1/1/2014
• Androgen receptor splice variants determine taxane sensitivity in prostate cancer  
  Thadani-Mulero M, Portella L, Sun S, Sung M, Vessella R, Nanus DM, Plymate S, Giannakakou P, Cancer Res, 1/1/2014
• In vitro method to observe E-selectin-mediated interactions between prostate circulating tumor cells derived from patients and human endothelial cells  
  Gakhar G, Bander NH, Nanus DM, J Vis Exp, 1/1/2014
• The role of HIF1alpha in renal cell carcinoma tumorigenesis  
  Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM, J Mol Med, 1/1/2014
• Anti-tumor effect of novel cationic biomaterials in prostate cancer  
  Gakhar G, Liu H, Shen R, Scherr D, Wu DQ, Nanus D, Chu CC, Anticancer Res, 1/1/2014
• ERG induces taxane resistance in castration- resistant prostate cancer  
  Galletti G, Matov M, Beltran H, Fontugne J, Mosquera JM, Cheung C, MacDonald TY, Sung M, O'Toole S, Kenc JG, Chae SS, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvat..., Nature Commun, 1/1/2014
• Immunologics and chemotherapeutics for renal cell carcinoma  
  Diamond E, Riches J, Faltas B, Tagawa ST, Nanus DM, Semin Intervent Radiol, 1/1/2014
• Activation of HIF2alpha in kidney proximal tubule cells causes abnormal glycogen deposition but not tumorigenesis  
  Fu L, Wang G, Shevchuk MM, Nanus DM, Gudas LJ, Cancer Res, 1/1/2013
• Phase II study of lutetium-177 labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 for metastatic castration-resistant prostate cancer  
  Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, Osborne J, Goldsmith SJ, Larson S, Taskar NP, Scher HI, Bander NH, Nanus DM, Clin Cancer Res, 1/1/2013
• Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in men with metastatic ...  
  Tagawa ST, Akhtar NH, Nikolopoulou A, Kaur G, Robinson B, Kahn R, Vallabhajosula S, Goldsmith SJ, Nanus DM, Bander NH, Front Rad Oncol, 1/1/2013
• 2-weekly versus 3-weekly docetaxel for prostate cancer  
  Nanus DM and Tagawa ST, Lancet Oncology, 1/1/2013
• A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802  
  Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J, Med Oncol, 1/1/2012
• Biomarkers in the management and treatment of men with metastatic castration- resistant prostate cancer  
  Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI, Eur Urol, 1/1/2012
• Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device  
  Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, Gleghorn JP, Santana SM, Liu H, Smith JP, Tagawa ST, Bander NH, Nanus DM, Giannakakou P, PLoS One, 1/1/2012
• Join now to see all

Books/Book Chapters

• ASCO-SEP Medical Oncology Self- Evaluation Program Version III 
  Chapter: Genitourinary Cancers 
  Nanus DM and Milowsky MIEditors: Moore A.American Society of Clinical Oncology2013
• Nuclear Medicine Therapy: Principles and Clinical Applications 
  Chapter: Radioimmunotherapy of prostate carcinoma. 
  Goldsmith SJ, Tagawa ST, Vallabhajosula S, Nikolopoulou A, Lipai I, Nanus DM, Bander NHEditors: Aktolun C and Goldsmith SJ.Springer Science+Business Media2013
• Targeted Therapies for Renal Cell Carcinoma 
  Chapter: Chemotherapy in metastatic RCC: A targeted approach in non-clear-cell and sarcomatoid/rapidly progressive RCC 
  Diamond E, Akhtar NH, Tagawa ST, Nanus DMEditors: Bukowski R.Future Science Group2012
• Targeted Radionuclide Therapy 
  Chapter: Targeted R radionuclide therapy for prostate cancer. 
  Bander NH, Vallabhajosula S, Goldsmith SJ, Tagawa ST, Nanus DNEditors: Speer TW.Lippincott Williams & Wilkins2010
• ASCO-SEP Medical Oncology Self- Evaluation Program Version II 
  Chapter: Genitourinary Cancers 
  Nanus DM and Milowsky MIEditors: Moore A.American Society of Clinical Oncology2010
• ASCO-SEP Medical Oncology Self- Evaluation Program 
  Chapter: Genitourinary Cancers 
  Nanus DM and Milowsky MIEditors: Moore A.American Society of Clinical Oncology2007
• Contemporary Management of Renal Cell Carcinoma 
  Chapter: Chemotherapeutic Strategies for Renal Cell Carcinoma 
  Page 601 - 609Milowsky MI and Nanus DMEditors: Taneja SS.W.B. Saunders Co., Philadelphia2003
• Atlas of Cancer 
  Chapter: Kidney Cancer 
  Page 443 - 449Milowsky MI, Del Pizzo JJ, Nanus DMEditors: Markman M.Markman M, Philadelphia2003
• Cell Surface Aminopeptidases: Basic and Clinical Aspects 
  Chapter: Neutral endopeptidase and other peptidases such as aminopeptidase A and dipeptidyl peptidase IV in the development and progression of cancer. 
  Page 119 - 128Nanus DM, Shen R, Dai J, Sumitomo MEditors: Mizutani S, Turner AJ, Nomura S, Ino K.Elsevier Science, Amsterdam2001
• Renal Cancer Methods and Protocols 
  Chapter: Orthotopic Model of Renal Cell Carcinoma 
  Page 245 - 253Nanus DM and Engelstein DEditors: Mydlo JH.Humana Press Inc., Totowa2001
• Classic Papers and Current Comments: Highlights of Genitourinary Cancer Research 
  Chapter: Antitumor effect of interferon alfa-2a and 13 cis-retinoic Acid in renal cell carcinoma: Results of a Phase II Trial and in vitro Studies. 
  Page 307 - 315Motzer RJ, Schwartz P, Murray-Law T, Hoffman AD, Albino AP, Vlamis V, Nanus DMEditors: Vogelzang NJ.WB Saunders Co., Philadelphia1997
• Cell-surface Peptidases 
  Chapter: Expression of cell-surface peptidases in neoplastic cells. 
  Page 353 - 369Nanus DM, Papandreou CN, Albino APEditors: Kenny J, Boustead CM.Bios Scientific Publishers Ltd., Oxford1997
• Current Problems in Cancer 
  Chapter: Renal cell carcinoma. 
  Page 185 - 232Motzer RJ, Russo P, Nanus DM, Berg WEditors: Ozols RF.Mosby, St. Louis1997
• Principles and Practice of Genitourinary Oncology 
  Chapter: Experimental Models of Renal Cancer 
  Page 779 - 7855. Nanus DM and Walker CLEditors: Raghavan D, Scher HI, Leibel SA, Lange P.J.B. Lippincott Co., Philadelphia1996
• Renal Cell Carcinoma: Immunotherapy and Cellular Biology 
  Chapter: Antiproliferative and antitumor effect of interferon-alpha in renal cell carcinoma. 
  Page 85 - 91Bander NH, Gastl GA, Nanus DM, Finstad CL, Albino AP, Pfeffer LMEditors: Klein E, Bukowski RM, Finke J.Marcel Dekker, Inc., New York1993
• Renal Cell Carcinoma: Immunotherapy and Cellular Biology 
  Chapter: Oncogene induced transformation of human kidney proximal tubule cells. 
  Page 53 - 65Nanus DM and Albino APEditors: Klein EA, Bukowski RM, Finke JH.Marcel Dekker, Inc., New York1993
• Basic and Clinical Research on Renal Cell Carcinoma 
  Chapter: Anti-proliferative and antitumor effect of alpha-interferon in renal cell carcinoma: Correlation with the expression of a kidney associated differentiation glycoprotein. 
  Page 115 - 120Bander NH, Gastl G, Nanus DM, Pfeffer LM, Finstad CL, Albino APEditors: Staehler G, Pomer S.Springer-Verlag, Berlin1992
• Join now to see all

Lectures

• Taxanes: Novel Combinations and Clinical States 
  Chicago, IL - 1/29/2015
• Circulating Tumor Cells in the Microenvironment 
  Lawrence Livermore National Laboratory, CA - 1/27/2015
• Advances and clinical trial opportunities in immunotherapy for GU cancers. 
  Las Vegas, NV - 1/13/2015
• Targeting Angiogenesis in the Treatment of Metastatic RCC; Targeting mTOR in the Treatment of Metastatic RCC 
  Washington, DC - 1/6/2014
• Preparing for a Faculty Career in an Academic Medical Center / Cancer Center 
  New York, NY - 1/4/2014
• Urologic Cancers: Prevention, Early Detection and Novel Therapies 
  Weill Cornell Medical College, New York, NY - 1/30/2013
• Capture and Analysis of CTCs in Prostate Cancer: Exploring Biomarkers of Taxane Sensitivity 
  Washington, DC - 1/21/2013
• Patients Living Longer: The Promise of Newer Therapies 
  Weill Cornell Medical College, New York, NY - 1/18/2013
• Management of Non-Clear Cell RCC 
  New York, NY - 1/6/2013
• Kidney Cancer; Test Taking Strategies 
  New York, NY - 1/3/2013
• Prostate Cancer 2012: Changes in Diagnosis and Treatment 
  New York Downtown Hospital, New York, NY - 1/9/2012
• Circulating Tumor Cell Capture in Prostate Cancer using GEDI Microfluidic Device: Clinical Applications 
  New York Academy of Medicine, New York, NY - 1/8/2012
• Circulating Tumor Cells in Prostate Cancer 
  New York, NY - 1/21/2011
• Update on Chemotherapy for Advanced Prostate Cancer 
  Paris, France, 2011; Normandy, France, 2011 - 1/11/2011
• Current Update in Targeted Therapy for Advanced Renal Cell Carcinoma 
  Paris, France, 2011; Normandy, France, 2011 - 1/11/2011
• Risk-Stratified Therapy for Renal Cell Carcinoma 
  New York, NY - 1/30/2010
• Metastatic Renal Cell Carcinoma: Single-Agent or Combination Therapy? 
  New York, NY - 1/16/2010
• Circulating Tumor Cell Capture and Analysis in Prostate Cancer 
  New York, NY - 1/12/2010
• Treating Advanced Renal Cell Carcinoma 
  New York, NY - 1/31/2009
• New Developments in Genitourinary Cancers, including Renal Cell Carcinoma and Prostate Cancer 
  New York, NY - 1/13/2009
• Changes and Challenges in the Treatment of Renal Cell Carcinoma 
  Larissa, Greece - 1/11/2009
• Targeted Therapies in Prostate and Renal Cancer 
  Buenos Aires, Argentina - 1/1/2009
• Treating Advanced Renal Cell Carcinoma Across Multiple Lines of Therapy 
  New York, NY - 1/25/2008
• Renal Cell Carcinoma 2008: Contemporary Management and Controversies 
  Larissa, Greece - 1/23/2008
• Prostate Carcinoma - Update 2008 
  New York, NY - 1/16/2008
• Join now to see all

Other

• Beyond the Abstract - Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer. 
  Beltran H, Nanus DM, Tagawa ST, UroToday.com
  1/30/2010
• Recent advances in management of renal cancer. 
  Shah JH, Nanus DM, f1000 Medicine Reports
  1/1/2009